CanSino Biologics has signed an agreement under which Pfizer will promote its meningitis vaccine candidate Menhycia in China, reported South China Morning Post.
“The agreement paves a way for a deepened tie-up with [Pfizer] and strengthens our commercial capabilities,” said Yu Xuefeng, chairman of CanSino. “It also lays a solid foundation for CanSino to consolidate a foothold in China while going international.”
According to pharmaceutical executives, the endorsement is significant after China was hit by a scandal that triggered a crisis of confidence in the domestic vaccine industry. In 2018, it was found that Changchun Changsheng Bio-technology supplied ineffective DPT vaccines and forged data on its rabies vaccine production procedures.
The NMPA has said it will prioritize the review of Menhycia, signalling that it would receive approval soon.
To read more NewsPoints articles, click here.